Glenza is a medication that contains the active substance enzalutamide. It is used in the treatment of prostate cancer. Here is a comprehensive description:

1. Active Substance: Enzalutamide

• Enzalutamide is the primary active ingredient in Glenza. It belongs to a class of medications known as androgen receptor inhibitors. Enzalutamide works by inhibiting the activity of androgen receptors, which play a crucial role in the growth and progression of prostate cancer.

2. Medical Indications:

• Glenza, with enzalutamide as the active ingredient, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is used in patients who have previously received androgen deprivation therapy but whose cancer has progressed despite this treatment.

3. Mechanism of Action:

• Enzalutamide exerts its anti-cancer effects by competitively inhibiting androgen receptors in prostate cancer cells. This interference suppresses the growth signals that contribute to the progression of prostate cancer.

4. Administration:

• Glenza is typically administered orally in the form of tablets. The dosage and administration schedule are determined by the treating oncologist based on the patient’s specific medical condition.

5. Purpose:

• Enzalutamide is employed to manage advanced prostate cancer that is no longer responsive to standard androgen deprivation therapy. It aims to slow down the progression of the disease and improve patient outcomes.

6. Manufacturer:

• Information about the manufacturer of Glenza may vary. It is essential to refer to the specific product packaging or consult with a healthcare professional for accurate details.

7. Side Effects:

• Enzalutamide may cause side effects, and their severity can vary among individuals. Common side effects include fatigue, back pain, hot flashes, hypertension, and nausea. Serious side effects may include seizures, so patients with a history of seizures should be closely monitored.

8. Precautions:

• Glenza, containing enzalutamide, should be used with caution in patients with a history of seizures, as it may increase the risk of seizure activity.
• Patients should inform their healthcare providers about all medications, including prescription and over-the-counter drugs, and any pre-existing medical conditions.

9. Contraindications:

• Enzalutamide is contraindicated in patients with a known hypersensitivity to the drug or its components.
• Pregnant women and women planning to become pregnant should avoid handling crushed or broken Glenza tablets due to the potential risk to a developing fetus.

10. Follow-up Monitoring:

• Patients receiving enzalutamide may require regular follow-up visits for monitoring of treatment efficacy, potential side effects, and adjustments to the treatment plan as needed.

Glenza, with enzalutamide as its active substance, represents a valuable therapeutic option for patients with advanced prostate cancer. The use of this medication is carefully determined by oncologists based on the individual patient’s condition and the specific characteristics of the cancer being treated. Patients are encouraged to communicate openly with their healthcare providers regarding any concerns or potential side effects during the course of treatment.